Integration of Novel Immunotherapies into
the Paradigm of MSI-positive mCRC

A continuing medical education activity sponsored by NAMCP and AAMCN.

New Horizons in the Treatment and Management of Metastatic Colorectal Cancer (mCRC): Best Practices for Improved Patient Outcomes is a multi-part series that will provide participants with the latest information on Metastatic Colorectal Cancer

This is Part II of the series focusing on Integration of Novel Immunotherapies
into the Paradigm of MSI-positive mCRC

This activity is an archive from the webinar held July 28, 2017. If you participated in the live webinar,
you are not eligible for credits for this activity.

This activity is valid from September 1, 2017 to September 30, 2018

Instructions for CME/CNE: Complete the pre test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.
 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Bayer Healthcare Pharmaceuticals and Merck Sharp & Dohme Corp

Description:
Colorectal cancer (CRC) is the development of cancer from the colon or rectum, due to the abnormal growth of cells that have the ability to invade or spread to other parts of the body. Excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States. In 2017, it is expected that there will be 134,490 new cases of colorectal cancer and 49,190 deaths. When discovered early, CRC is highly treatable. However, when the disease has spread, or metastasized, treatment and management becomes much more difficult. Fortunately, targeted- and immuno-therapy options have become available for patients with metastatic colorectal cancer (mCRC), giving clinicians and managed care professionals more options in managing this patient population. This is part 2 of a five-part webinar series that will look closely at the use of immunotherapies in MSI-positive mCRC.

Upon Completion of this activity, participants will be able to:

  • Discuss the role of immunotherapies in the treatment of MSI-positive mCRC

  • Review recent clinical data on immunotherapy in the management of MSI-positive mCRC

  • Individualize treatment with immunotherapeutic agents based on patient factors including tumor characteristics, treatment history, common adverse effects, and age for optimal care

  • Assess key sequencing considerations when formulating a plan for individualized treatment in MSI-positive mCRC
     

Faculty: Gerard Blobe, M.D., Ph.D.
Department of Medicine
Department of Pharmacology and Cancer Biology
Duke University Medical Center

Disclosure:

 Dr. Blobe serves as on the speaker’s bureau to Genentech/Roche; serves as a consultant for Genentech/Roche and has received income in any amount from Genentech/Roche. His presentation has been peer reviewed for any bias.
 
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.
Jacquelyn Smith has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by educational grants from
Bayer Healthcare Pharmaceuticals and Merck Sharp & Dohme Corp

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue